Regeneron stock weighs early CIDEB data and pipeline webcast

Published on 11/10/2026 at 15:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock is in focus after new CIDEB data showed sustained liver-fat reductions in an early MASLD trial. Management scheduled a pipeline webcast.

CIDEB data sharpen pipeline focus

Regeneron reported sustained liver-fat reductions from a single investigational CIDEB siRNA dose in adults with MASLD.
The Phase 1/2 program is advancing while longer-term safety and histologic outcomes remain under evaluation.
Management scheduled a virtual investor event on November 10 to discuss the cardiometabolic and MASH pipeline.

Regeneron, US75886F1075, Illustration mit AI erstellt.

Regeneron Pharmaceuticals said on Sunday, November 8, that a single investigational CIDEB siRNA dose produced sustained liver-fat reductions in adults with metabolic dysfunction-associated steatotic liver disease. The company released the results ahead of a virtual investor event on Tuesday, November 10, focused on its cardiometabolic and MASH pipeline.

According to Regeneron's release, the Phase 1/2 first-in-human trial tested one subcutaneous dose across four dose levels in 30 participants receiving CIDEB siRNA and compared them with 10 placebo recipients. Safety and tolerability were the primary objectives, while liver fat and liver-injury markers were secondary measures.

Early data support further development

Liver fat fell by 58% to 80% at week 36 among CIDEB siRNA recipients, measured by MRI-PDFF. The reductions had reached 49% to 72% at week six. The placebo group recorded a mean reduction of 2.9% at week 36.

At week 36, liver fat was below 5% in 62% of treated participants, compared with none in the placebo group. Regeneron also said 93% of treated participants achieved at least a 30% reduction in liver fat, a threshold associated with histological MASH resolution. Improvements in ALT and directionally similar changes in AST were sustained through week 36.

The findings remain early clinical evidence rather than approval data. Regeneron said longer-term safety and histologic outcomes are being evaluated in ongoing Phase 2a, Phase 2b and Phase 3 studies. The company stated that the potential uses of CIDEB siRNA are investigational and have not been evaluated by a regulatory authority.

Pipeline event sets next investor focus

Regeneron scheduled a virtual Regeneron Roundtable for Tuesday, November 10, at 8:30 a.m. Eastern time to discuss its cardiometabolic and MASH programs. The company said a replay would be archived on its website for at least 30 days.

Regeneron stock traded at 819.05 euros on Lang & Schwarz at 15:02 CET on Tuesday, November 10. The biotechnology company's pipeline remains a key investor focus as the CIDEB program moves toward larger and longer clinical studies.